bpc 157 dry eyes BPC-157 – Research Peptide Can the SS-31 Peptide Stop

This is typically temporary and resolves within a few days

This is mechanistically distinct from proton pump inhibitor pharmacology and is part of why the peptide attracts interest as a research tool for ulcer biology and NSAID-induced gastric injury

Malignancy: Oncology referral for appropriate cancer treatment (surgery, chemotherapy, radiotherapy)

How it works: The stack pairs BPC-157 for targeted repair support with TB-500 for broader tissue recovery, mobility, and cell migration support

Duration: Research protocols often run 8 to 12 weeks minimum, with some extending to 6 months for thymosin alpha-1 to allow full Treg population recovery